Status and phase
Conditions
Treatments
About
This is a single-arm open-label phase I/II study to determine the relative superiority of αCD19-TCRζ-CD28 and αCD19-TCRζ-CD137 CAR-T Cells in safety, efficacy and engraftment potential in patients with CD19+ B-lineage leukemia and lymphoma. Recently, cancer immunotherapy, treatments aiming to arm patients with immunity specifically against cancer cells, has emerged as a promising therapeutic strategy. Clinical trials utilizing CARs against B cell malignancies have demonstrated remarkable potential. In this trial, all subjects will be competitively infused with αCD19-TCRz-CD28 and αCD19-TCRz-CD137 CAR-T cells in equal number to test a hypothesis that CD137-costimulation can promote the persistence and engraftment of CAR-T cells and this superiority can lead to improved progression-free survival.
Full description
Primary objectives
Secondary objectives
To measure the efficacy of anti-tumor responses after CD19CAR T cell infusion To determine if CD19CAR T cells engineered with 4-1BB signaling domain is superior to that with CD28 signaling domain for their homing and persistence after CD19CAR T cell infusion
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
5 Years to 70 Years, Male and female;
Expected survival > 12 weeks;
Performance score 0-2;
Histologically confirmed as CD19-positive lymphoma/leukemia and who meet one of the following conditions;
Creatinine < 2.5 mg/dl;
ALT/AST < 3x normal;
Bilirubin < 2.0 mg/dl;
Adequate venous access for apheresis, and no other contraindications for leukapheresis;
Take contraceptive measures before recruit to this trial;
Written voluntary informed consent is given.
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
20 participants in 1 patient group
Loading...
Central trial contact
Zhi Cheng, M.D.
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal